Newswise — Alameda, CA. -- July 31, 2013 -- Singulex, Inc., first to commercialize Single Molecule Counting (SMC) technology and committed to improving patient care and enabling the reduction of healthcare costs by providing high-value, advanced tests and systems for the diagnosis and monitoring of chronic diseases, today announced that the AACC has recognized two studies featuring Singulex’s Erenna® technology with the National Academy of Clinical Biochemistry’s Distinguished Abstract Award at its Annual Meeting being held in Houston, TX.
The research (Abstract B-175, Determination of Cardiac Troponin with a Single-Molecule High-Sensitivity Assay and Outcomes in Patients with Stable Coronary Artery Disease: Analysis from PROVE IT-TIMI 22) presented by Petr Jarolim, M.D., Ph.D., Associate Professor of Pathology at Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, demonstrated that even minor elevations of c-TnI (cardiac troponin) predicted long-term outcomes, including increased risk of death, for cardiovascular patients with stable ischemic heart disease after a prior acute coronary event. Use of Erenna technology to measure previously undetectable biomarkers, such as c-TnI, revealed that patients with elevated c-TnI had a reduction in death and heart failure when treated with intensive statin therapy. This research study was selected for an oral presentation during the Chronic Disease and Clinical Outcomes session on Monday, July 29, 2013.
“Cardiovascular disease is a major problem worldwide and the ability to identify patients at risk and prescribe appropriate treatment is a vital step in reducing the health and economic burden of this disease,” said Dr. Jarolim. “The technology, which we were able to use in our research, provided us the unique opportunity to measure cardiac troponin at previously undetectable levels, giving physicians a more efficient way to monitor patients that are at risk of clinical worsening and death.”
The research (Abstract B-196, Use Of Novel Plasma Biomarkers To Predict Hospitalization in Chronic Heart Failure Patients) led by Robert H. Christenson, Ph.D., DABCC, FACB and professor of pathology at University of Maryland, assessed the prognostic performance of several novel and established biomarkers for heart failure. Of the panel of biomarkers tested, high sensitive c-TnI and endothelin, markers for vascular function, were the strongest predictors of heart failure. Both these markers were assessed using Erenna technology. This research study will be presented during the Cardiac Markers Poster Session on Wednesday, July 31, 2013.
“We are proud of the great work being presented by our collaborators and congratulate them on this well-deserved honor,” said Guido Baechler, president and CEO of Singulex. “We were first to establish and commercialize the single molecule counting technology several years ago into our Life Sciences business with much success. Since 2010, as part of our Advanced Testing Services, our CAP and CLIA -certified lab has processed more than 3 million clinical tests allowing physicians to monitor patients in a chronic setting.”
About the Erenna PlatformThe Erenna Research Use Only platform, powered by Singulex’s proprietary SMC technology, detects low-abundance biomarkers with precision and sensitivity that has not previously been achievable, even detecting single molecules to the femtogram levels. The technology’s ability to measure small changes in biomarkers, such as cardiac troponin I, cytokines, and other inflammatory markers, and to monitor these changes over time has expanded the clinical utility of established markers while providing researchers and clinicians the opportunity to gain insights from discovery to clinical applications in cardiovascular disorders and other diseases.
About Singulex, Inc.Singulex’s vision is to transform chronic disease management, improving patient care and health while reducing healthcare costs. Singulex’s proprietary digital immunoassay platform significantly increases the diagnostic and prognostic power of established biomarkers. This enables physicians to individualize treatment strategies, monitor effectiveness of therapy and encourage patient adherence through feedback. Improved patient outcomes and the reduced need for costly, invasive diagnostic procedures translate into healthcare cost savings. The Singulex CLIA-certified laboratory offers a comprehensive menu of advanced cardiovascular disease testing to physicians in the U.S. At leading pharmaceutical R&D laboratories, academic institutions and clinical research organizations (CROs) around the world, digital immunoassay technology from Singulex is powering discovery and development of innovative diagnostics and treatments for chronic diseases such as CVD, Alzheimer, arthritis and diabetes. For further information, visit www.singulex.com.
Media:Denise PowellBrewLife510.703.9491 [email protected]
Investors:Michael Bell, Chief Financial OfficerSingulex, [email protected]